{"id":"mifegyne-and-cytotec","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Abdominal pain"},{"rate":"10-30%","effect":"Headache"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Dizziness"},{"rate":"5-20%","effect":"Bleeding"},{"rate":"5-20%","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Mifepristone, a progesterone receptor antagonist, is used in combination with misoprostol, a prostaglandin E1 analog, to induce uterine contractions and terminate pregnancy. This combination works by blocking the action of progesterone, which is essential for maintaining pregnancy, and inducing uterine contractions, which helps to expel the embryo or fetus.","oneSentence":"Mifepristone blocks progesterone receptors, while misoprostol induces uterine contractions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:27.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Medical abortion"}]},"trialDetails":[{"nctId":"NCT06733727","phase":"NA","title":"Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-12-06","conditions":"Silent Miscarriage","enrollment":884},{"nctId":"NCT03659045","phase":"NA","title":"Pain Assessment in MToP Up to 7 WA (during 5h After Misoprostol Intake)","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-01-15","conditions":"Abortion-Related Disorders","enrollment":320},{"nctId":"NCT01862991","phase":"NA","title":"Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-07","conditions":"Legally Induced Abortion Without Mention of Complication","enrollment":80},{"nctId":"NCT01615731","phase":"NA","title":"Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-05","conditions":"Abortion, Induced","enrollment":50},{"nctId":"NCT02412618","phase":"PHASE4","title":"Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2012-09","conditions":"Induced Abortion","enrollment":100},{"nctId":"NCT05124314","phase":"PHASE4","title":"Comparison of Two Different Drug Regimens for Medical Treatment of Early Pregnancy Loss","status":"UNKNOWN","sponsor":"Clinical Hospital Merkur","startDate":"2021-10-27","conditions":"Abortion, Missed","enrollment":220},{"nctId":"NCT02704481","phase":"PHASE4","title":"Non-surgical Alternatives to Treatment of Failed Medical Abortion","status":"TERMINATED","sponsor":"Gynuity Health Projects","startDate":"2016-06-01","conditions":"Abortion Failure","enrollment":16},{"nctId":"NCT03320057","phase":"PHASE4","title":"Medication Abortion Via Pharmacy Dispensing","status":"COMPLETED","sponsor":"Daniel Grossman","startDate":"2018-06-01","conditions":"Pregnancy Related, Abortion Early","enrollment":326},{"nctId":"NCT03212352","phase":"PHASE4","title":"Comparing Two Medical Treatments for Early Pregnancy Failure.","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-06-27","conditions":"Early Pregnancy Failure","enrollment":342},{"nctId":"NCT03065660","phase":"PHASE3","title":"Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2017-09-20","conditions":"Missed Miscarriage","enrollment":711},{"nctId":"NCT02679092","phase":"NA","title":"Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2016-04","conditions":"Legally Induced Abortion Without Mention of Complication","enrollment":""},{"nctId":"NCT03829696","phase":"PHASE4","title":"Advance Provision of Medication Abortion","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2020-01","conditions":"Early Abortion","enrollment":""},{"nctId":"NCT02708446","phase":"PHASE4","title":"A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion","status":"UNKNOWN","sponsor":"Gynuity Health Projects","startDate":"2014-05","conditions":"Legally Induced Abortion Without Mention of Complication","enrollment":320},{"nctId":"NCT02720991","phase":"PHASE4","title":"A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks","status":"COMPLETED","sponsor":"Gynuity Health Projects","startDate":"2014-07","conditions":"Abortion, 3 Months","enrollment":50},{"nctId":"NCT01751087","phase":"NA","title":"Cervical Preparation Before Dilation and Evacuation","status":"COMPLETED","sponsor":"Planned Parenthood League of Massachusetts","startDate":"2013-01","conditions":"Abortion, Induced","enrollment":300},{"nctId":"NCT01795599","phase":"PHASE3","title":"Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2013-05","conditions":"Surgical Abortion","enrollment":198},{"nctId":"NCT00920465","phase":"PHASE3","title":"Treatment Regimens for Mifegyne and Cytotec","status":"UNKNOWN","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2009-06","conditions":"Medical Abortion","enrollment":200},{"nctId":"NCT00945997","phase":"NA","title":"Misoprostol for Second Trimester Termination of Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2000-10","conditions":"Termination of Pregnancy Second Trimester","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Comparison of one day dosing to two days dosing"],"phase":"phase_3","status":"active","brandName":"mifegyne and cytotec","genericName":"mifegyne and cytotec","companyName":"Western Galilee Hospital-Nahariya","companyId":"western-galilee-hospital-nahariya","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mifepristone blocks progesterone receptors, while misoprostol induces uterine contractions. Used for Medical abortion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}